PURPOSE: To estimate the benefit and cost of using radiotherapy (RT) in the initial management of lung cancer in the general population. METHODS: We identified indications for RT in the initial management of small cell and non-small cell lung cancer through a review of the literature. The proportion of patients with each specific indication for treatment was determined using epidemiological observations from cancer registry data and from the literature. We estimated the benefit gained from RT use for each indication in the model using values published in the literature. We estimated the cost of RT for each indication using published Canadian data. The total benefit and cost was calculated for all indications combined. Results are reported in 2001 Canadian dollars. RESULTS: The mean benefit was 7 months of survival for each lung cancer patient treated with curative intent and 3 months of symptom control for each patient treated with palliative intent. The average cost was 9881 dollars per life year gained and 13,938 dollars per year of symptom control gained. Sensitivity analysis revealed values between 7905 dollars and 19,762 dollars per year of survival gain and between 10,368 dollars and 27,875 dollars per year of symptom control gained. CONCLUSIONS: Using RT in the initial management of lung cancer can provide considerable gains in survival and symptom control. The cost of RT for the initial management of lung cancer is inexpensive compared with a common cut off of 50,000 dollars per life year gained.
PURPOSE: To estimate the benefit and cost of using radiotherapy (RT) in the initial management of lung cancer in the general population. METHODS: We identified indications for RT in the initial management of small cell and non-small cell lung cancer through a review of the literature. The proportion of patients with each specific indication for treatment was determined using epidemiological observations from cancer registry data and from the literature. We estimated the benefit gained from RT use for each indication in the model using values published in the literature. We estimated the cost of RT for each indication using published Canadian data. The total benefit and cost was calculated for all indications combined. Results are reported in 2001 Canadian dollars. RESULTS: The mean benefit was 7 months of survival for each lung cancerpatient treated with curative intent and 3 months of symptom control for each patient treated with palliative intent. The average cost was 9881 dollars per life year gained and 13,938 dollars per year of symptom control gained. Sensitivity analysis revealed values between 7905 dollars and 19,762 dollars per year of survival gain and between 10,368 dollars and 27,875 dollars per year of symptom control gained. CONCLUSIONS: Using RT in the initial management of lung cancer can provide considerable gains in survival and symptom control. The cost of RT for the initial management of lung cancer is inexpensive compared with a common cut off of 50,000 dollars per life year gained.